Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 173 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2017, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 6, 5, 10, 1, 13, 6 and 3 respectively.

Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents
 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ankylosing Spondylitis (Bekhterev's Disease) - Overview 8
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Products under Development by Companies 13
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 24
AbbVie Inc 24
Adello Biologics LLC 24
Allergan Plc 25
Alteogen Inc 25
Amgen Inc 26
Biocad 26
Biocon Ltd 27
Bionovis SA 27
Celgene Corp 28
Coherus BioSciences Inc 28
Galapagos NV 29
Genor BioPharma Co Ltd 29
Immunwork Inc 30
Innovent Biologics Inc 30
Johnson & Johnson 31
Merck KGaA 31
Momenta Pharmaceuticals Inc 32
Mycenax Biotech Inc 32
Novartis AG 33
Oncobiologics Inc 33
Protalix BioTherapeutics Inc 34
Reliance Life Sciences Pvt Ltd 34
Sandoz International GmbH 35
Shanghai Pharmaceutical Co Ltd 35
Sun Pharma Advanced Research Company Ltd 36
UCB SA 36
Xbrane Biopharma AB 37
Ankylosing Spondylitis (Bekhterev's Disease) - Drug Profiles 38
adalimumab biosimilar - Drug Profile 38
adalimumab biosimilar - Drug Profile 40
adalimumab biosimilar - Drug Profile 41
adalimumab biosimilar - Drug Profile 42
adalimumab biosimilar - Drug Profile 43
adalimumab biosimilar - Drug Profile 44
adalimumab biosimilar - Drug Profile 45
adalimumab biosimilar - Drug Profile 47
adalimumab biosimilar - Drug Profile 50
adalimumab biosimilar - Drug Profile 51
adalimumab biosimilar - Drug Profile 52
adalimumab biosimilar - Drug Profile 54
adalimumab biosimilar - Drug Profile 55
adalimumab biosimilar - Drug Profile 56
apremilast - Drug Profile 57
BAT-1406 - Drug Profile 68
BCD-085 - Drug Profile 69
bimekizumab - Drug Profile 70
certolizumab pegol biosimilar - Drug Profile 72
DNX-114 - Drug Profile 73
DNX-514 - Drug Profile 74
etanercept biosimilar - Drug Profile 75
etanercept biosimilar - Drug Profile 77
etanercept biosimilar - Drug Profile 79
etanercept biosimilar - Drug Profile 80
etanercept biosimilar - Drug Profile 81
etanercept biosimilar - Drug Profile 82
etanercept biosimilar - Drug Profile 86
etanercept biosimilar - Drug Profile 87
etanercept biosimilar - Drug Profile 90
filgotinib - Drug Profile 91
golimumab - Drug Profile 103
golimumab biosimilar - Drug Profile 112
golimumab biosimilar - Drug Profile 113
HEISCO-III-002 - Drug Profile 114
infliximab biosimilar - Drug Profile 115
infliximab biosimilar - Drug Profile 116
infliximab biosimilar - Drug Profile 117
infliximab biosimilar - Drug Profile 120
infliximab biosimilar - Drug Profile 121
infliximab biosimilar - Drug Profile 122
infliximab biosimilar - Drug Profile 123
risankizumab - Drug Profile 124
secukinumab - Drug Profile 128
TE-2122 - Drug Profile 141
TE-2158 - Drug Profile 142
thalidomide - Drug Profile 143
tildrakizumab - Drug Profile 144
upadacitinib tartrate - Drug Profile 147
VTP-43742 - Drug Profile 151
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 154
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 156
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 157
Featured News & Press Releases 157
Appendix 169
Methodology 169
Coverage 169
Secondary Research 169
Primary Research 169
Expert Panel Validation 169
Contact Us 169
Disclaimer 170

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Adello Biologics LLC, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Allergan Plc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alteogen Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocad, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Ltd, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bionovis SA, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corp, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Coherus BioSciences Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Galapagos NV, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co Ltd, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Immunwork Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Merck KGaA, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics Inc, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by UCB SA, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Xbrane Biopharma AB, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H1 2017